CompletedPhase 2

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

United States120 participantsStarted 2017-10-13

Plain-language summary

To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * be at least 18 years old * be willing and able to avoid all disallowed medications and contact lenses * must have a pregnancy test if of childbearing potential * must be able to read an eye chart from 10 feet away Exclusion Criteria: * must not have any allergies to the study medications * must not have any ocular or non ocular condition that investigator feels will interfere with study parameters * must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1

Timeframe: post CAC exposure at 5, 7, and 10 minutes post CAC on Day 1

Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 15

Timeframe: post CAC exposure at 5, 7, and 10 minutes post CAC on Day 15

Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 1

Timeframe: post CAC exposure at 7, 15, and 20 minutes post-CAC on Day 1.

Conjunctival Redness at 7, 15, and 20 Minutes Post CAC on Day 15

Timeframe: post CAC exposure at 7, 15, and 20 minutes post-CAC on Day 15.

Trial details

NCT IDNCT03320434

SponsorORA, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-02-16

Results submitted2022-07-11

View on ClinicalTrials.gov More Allergic Conjunctivitis trials